StreetInsider.com News Articles

Form DEFM14A Personalis, Inc.

Wed, 21 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261021/27216752.html

Form 425 Personalis, Inc. Filed by: Personalis, Inc.

Wed, 21 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261021/27212449.html

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

Wed, 21 Oct 2026 06:00:00 -0400

Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3 study in cutaneous squamous

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

Wed, 21 Oct 2026 06:00:00 -0400

Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer

Form 425 Personalis, Inc. Filed by: Personalis, Inc.

Tue, 20 Oct 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20261020/27211318.html

Form SC 13E3/A Personalis, Inc. Filed by: Personalis, Inc.

Tue, 20 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261020/27211162.html

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Tue, 20 Oct 2026 06:00:00 -0400

Real-Time Variant Tracker™ supplemental results track resistance and therapeutically targetable variants as cancer biology evolves.

FREMONT, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing. Real-Time Variant Tracker includes variants with established clinical significance, including associations with FDA-approved therapies and recommendations in National Comprehensive Cancer Network® (NCCN®) guidelines.

“At Personalis, we have continued to push the boundaries

Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Tue, 20 Oct 2026 06:00:00 -0400

Real-Time Variant Tracker™ supplemental results track resistance and therapeutically targetable variants as cancer biology evolves.

“At Personalis, we have continued to push the boundaries

Form 425 Personalis, Inc. Filed by: Personalis, Inc.

Tue, 06 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261006/27155535.html

Form 8-K Personalis, Inc. For: Oct 02

Tue, 06 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261006/27155471.html

BTIG Downgrades Personalis (PSNL) to Neutral

Tue, 06 Oct 2026 05:51:03 -0400

(Updated - October 6, 2026 5:51 AM EDT)

BTIG analyst Mark Massaro downgraded Personalis (NASDAQ: PSNL) from Buy to Neutral.

The analyst comments "We downgrade Personalis from Buy to Neutral as we are now increasingly confident that Tempus (TEM, Buy, $80 PT) will complete its acquisition of Personalis likely over the coming months. Recall that on July 20, 2026, Tempus agreed to acquire Personalis for $1.7 billion (which we wrote about here.) We were not surprised to see Tempus as the buyer, but there were terms of the deal that caught us and others by surprise, and the premium valuation (at ~17x

BTIG Downgrades Personalis (PSNL) to Neutral

Tue, 06 Oct 2026 05:51:03 -0400

(Updated - October 6, 2026 5:51 AM EDT)

BTIG analyst Mark Massaro downgraded Personalis (NASDAQ: PSNL) from Buy to Neutral.

Form SC 13E3/A Personalis, Inc. Filed by: Personalis, Inc.

Fri, 02 Oct 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20261002/27143366.html

Form CT ORDER Personalis, Inc.

Fri, 02 Oct 2026 09:35:00 -0400

si-local-file:///var/storage/secattach/20261002/27139690.html

Form 4 Personalis, Inc. For: Sep 18 Filed by: Tachibana Aaron

Tue, 22 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091144.html

Form 4 Personalis, Inc. For: Sep 18 Filed by: Hall Christopher M

Tue, 22 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091147.html

Form 4 Personalis, Inc. For: Sep 18 Filed by: Moore Stephen Michael

Tue, 22 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091148.html

Form 4 Personalis, Inc. For: Sep 18 Filed by: Chen Richard

Tue, 22 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091150.html

Form 425 Personalis, Inc. Filed by: Tempus AI, Inc.

Tue, 15 Sep 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260915/27065901.html

Craig-Hallum Downgrades Personalis (PSNL) to Hold

Mon, 24 Aug 2026 08:53:31 -0400

Craig-Hallum analyst John Wilkin downgraded Personalis (NASDAQ: PSNL) from Buy to Hold.

For an analyst ratings summary and ratings history on Personalis click here. For more ratings news on Personalis click here.

Shares of Personalis closed at $18.38 yesterday.

Form 8-K Personalis, Inc. For: Aug 20

Thu, 20 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260820/26956778.html

Form 8-K Personalis, Inc. For: Aug 20

Thu, 20 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260820/26956778.html

Form SCHEDULE 13G/A Personalis, Inc. Filed by: AMERIPRISE FINANCIAL INC

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926152.html

Form SCHEDULE 13G/A Personalis, Inc. Filed by: AMERIPRISE FINANCIAL INC

Fri, 14 Aug 2026 10:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26926152.html

Form SCHEDULE 13G/A Personalis, Inc. Filed by: Deep Track Capital, LP

Fri, 14 Aug 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26925187.html